Finance

Blood plasma volume expander developer reports loss of $0.02 per share

Published in Blood Weekly, December 15th, 2005

BioTime's total quarterly revenue increased 41% to $240,432 for the third quarter of 2005, from $170,381 for the same period last year.

BioTime's third quarter revenues for 2005 include $87,541 in funds as part of a $299,990 grant from the National Heart, Lung, and Blood Institute division of the National Institutes of Health (NIH) for use in the development of HetaCool.

The NIH grant was renewed in April 2005 following the submission of a satisfactory progress report on the project. BioTime did not recognize any grant revenue in the same period last year.

Royalty revenues from Hextend product sales in the United States and Canada...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2005-12-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry